NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

副神經節瘤治療藥的全球市場 (2020年∼2027年)

Global Paraganglioma Treatment Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004992
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
副神經節瘤治療藥的全球市場 (2020年∼2027年) Global Paraganglioma Treatment Market - 2020-2027
出版日期: 2021年05月12日內容資訊: 英文 180 Pages
簡介

全球副神經節瘤轉動治療藥的市場規模成長的主要因素有副神經節瘤發病率增加、生活方式改變、臨床試驗增加、新藥研發不斷努力、醫療成本增加等,預計未來受以上因素影響,擴張趨勢將持續。根據治療類型,肽受體放射性核素治療 (PRRT) 是最大的部分。按地區劃分,雖然北美國家引領全球市場,但預計亞太國家市場也將出現顯著增長。

本報告提供全球副神經節瘤治療藥的市場相關分析,提供市場規模趨勢預測,及各產生源·各治療類型·各終端用戶·各地區的詳細趨勢,主要的推動及阻礙市場要素,主要企業的簡介等相關調查。

目錄

第1章 全球副神經節瘤治療藥市場:分析方法·範圍

第2章 全球副神經節瘤治療藥市場:市場定義和概要

第3章 全球副神經節瘤治療藥市場:摘要整理

第4章 全球副神經節瘤治療藥市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球副神經節瘤治療藥市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球副神經節瘤治療藥市場:新型冠狀病毒感染疾病 (COVID-19)的分析

  • COVID-19對市場的影響分析
    • "COVID-19前" /過去的市場方案
    • "COVID-19中" /目前市場方案
    • "COVID-19後" /未來市場方案
  • COVID-19疫情中的價格趨勢
  • 需求與供給的變動階段
  • 感染擴大時政府的市場相關配合措施
  • 各製造公司的策略展開情形
  • 結論

第7章 全球副神經節瘤治療藥市場:各產生源

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各產生源
  • 市場向心力指數:各產生源
    • 迷走神經副神經節瘤
    • 頸椎副神經節瘤
    • 其他

第8章 全球副神經節瘤治療藥市場:各治療類型

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各治療類型
  • 市場向心力指數:各治療類型
    • 肽受體放射性核種療法 (PRRT)
    • 手術
    • 化療
    • 放射治療
    • 其他

第9章 全球副神經節瘤治療藥市場:各終端用戶

  • 簡介
  • 市場規模的分析與與前一年同期相比成長率 (YoY):各終端用戶
  • 市場向心力指數:各終端用戶
    • 醫院
    • 專門診所
    • 癌症研究機關
    • 其他

第10章 全球副神經節瘤治療藥市場:各地區

  • 簡介
  • 市場規模和與前一年同期相比成長率 (YoY):各地區
  • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模·與前一年同期相比成長率 (YoY):各產生源
    • 市場規模·與前一年同期相比成長率 (YoY):各治療類型
    • 市場規模·與前一年同期相比成長率 (YoY):各終端用戶
    • 市場規模·與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球副神經節瘤治療藥市場:競爭情形

  • 競爭方案
  • 市場定位/佔有率分析
  • 企業合併·收購 (M&A)的分析

第12章 全球副神經節瘤治療藥市場:企業簡介

  • Advanced Accelerator Applications
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Progenics Pharmaceuticals, Inc,
  • AstraZeneca,
  • Jubilant Life Sciences Ltd,
  • Pfizer Inc,
  • Teva Pharmaceutical Industries Ltd,
  • Cipla Inc,
  • Amneal Pharmaceuticals LLC,
  • Apotex Inc,
  • Ono Pharmaceuticals.

第13章 全球副神經節瘤治療藥市場:重要考察

第14章 關於DataM Intelligence

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The Global Paraganglioma Treatment Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Paraganglioma is a neuroendocrine tumor that forms near certain blood vessels and nerves outside of the adrenal glands. The adrenal glands are essential for making hormones that control many functions in the body and are located on top of the kidneys, and the nerve cells involved in paraganglioma are part of the peripheral nervous system. These tumors can also be called Extra-adrenal pheochromocytomas. Approximately 35-50% of paragangliomas may spread to other parts of the body. It is most often found in people aged 30 to 50 years old. Some signs and symptoms of paraganglioma occur when too much adrenaline or noradrenaline is released into the blood are High blood pressure, Headache, Heavy sweating for no known reason, A strong, fast, or irregular heartbeat, being shaky, Being extremely pale. The treatment includes Surgery, Radiation therapy, Chemotherapy, Ablation therapy, Embolization therapy, Targeted therapy. The market is expected to drive in the future due to the increasing prevalence rate of rare cancers.

Market Dynamics

The global Paraganglioma Treatment market growth is driven by the growing prevalance of paraganglioma cases, rapidly changing life style, growing number of clinical trials of drugs and continuous advancements in novel treatments, Rising healthcare expenditure are the major factors driving the market.

Increase Prevalence of Paraganglioma Cancers, is expected to drive the market during the forecast period.

As per the National Library of Medicine, it is estimated that the prevalence of pheochromocytoma is 1 in 500,000 people, and the prevalence of other paragangliomas is 1 in 1 million people. These statistics include syndromic and non-syndromic paraganglioma and pheochromocytoma.

Increased Drug approvals, is expected to drive the market during the forecast period.

Enterome is a clinical-stage company conducting a Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination with Immune Check Point Blockade (nivolumab) Treatment of Patients with Locally Advanced or Metastatic Malignant Pheochromocytoma/Paraganglioma.

Molecular Insight Pharmaceuticals, Inc got approval for marketing by conducting a study on expanded access of AZEDRA (Ultratrace Iobenguane I 131) and to evaluate the safety and tolerability of AZEDRA in subjects with iobenguane-avid malignant and recurrent pheochromocytoma/paraganglioma (PPGL).

Lack of awareness about the disease is likely to hinder the market growth.

Government and private organisations should initiate and implement awareness programs about the paraganglioma cancer as it is a rare type of cancer it may lead to advanced stage under no proper guidence and awareness. This may hamper the market growth majorly.

Segment Analysis

Based on Treatment Type, the global Paraganglioma Treatment market is segmented into Surgery, Peptide Receptor Radionuclide Therapy (PRRT) Chemotherapy, Radiation therapy.

Peptide Receptor Radionuclide Therapy (PRRT) segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)

Radionuclide therapy implicates the usage of radiolabeled peptides with high affinity to the involved receptor. In addition to surgery and chemotherapy, 131I-MIBG (Azedra) treatment has been effectively used to manage malignant and metastatic Paraganglioma cancers. In August 2018, Progenics Pharmaceuticals, Inc received approval from the FDA for Azedra (iobenguane I131), a radioactive therapeutic agent for locally advanced or metastatic treatment pheochromocytoma or paraganglioma in adult and pediatric patients 12 years and older. It has also received Breakthrough Therapy designation, an Orphan Drug designation, Fast Track designations and Priority Review from the FDA to treat iobenguane-avid metastatic paraganglioma and pheochromocytoma. The approval of Azedra represents significant advances in non-surgical treatment for ultra-rare cancer paraganglioma.

Additionally, Advanced Accelerator Applications has recently been used in metastatic Paraganglioma cancers, 177Lu-DOTATATE (Lutathera®) therapy.

Based on Site of Origin, the global Paraganglioma Treatment market is segmented into Carotid paragangliomas, Vagal paragangliomas, Cervical paragangliomas.

Carotid paragangliomas appear with an expanding and pulsing mass. When this paraganglioma appears as a superficial, isolated lesion, you may experience relatively few symptoms. These tumors usually appear in the neck but can extend into the space between the head and the neck.

Cervical paragangliomas are slow-growing tumors that can cause palsy and spread into the skull base. It can be challenging to distinguish between tumors that affect the vagus and those that involve the carotid artery.

Vagal paragangliomas can cause paralysis to the lower cranial nerves (including the 10th cranial nerve, which can cause paralysis of the diaphragm), 12th cranial nerve paralysis (with paralysis of the tongue), problems in swallowing, and problems with raising your shoulder.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centres for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Based on End-User, the global Paraganglioma Treatment market is segmented into Hospitals, Cancer Research centers, Speciality Clinics, others.

Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.

Geographical Analysis

North America served the largest share of the market due to the presence of major market players developing oncology products. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel radionuclide therapy and Radiation therapy methods, the total availability of advanced diagnostic tools. For instance, Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and / or Symptomatic Tumors With Somatostatin Receptor Overexpression is under phase 2 clinical trials by University of Warmy and Mazury.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Ono Pharmaceuticals, Yervoy injection (Ipilimumab) Anti-CTLA-4 antibody is under Phase 3 clinical trials to treat patients with Head and Neck cancers.

Competitive Landscape

The global Paraganglioma Treatment market is quite competitive with some key competitors like Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Apotex Inc, Ono Pharmaceuticals. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors.

For instance, according to clinicaltrials.gov; A Phase II Study to Evaluate the Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas by M.D. Anderson Cancer Center in Collaboration with National Cancer Institute (NCI).

Advanced Accelerator Applications

Company Overview: Advanced Accelerator Applications (AAA) was founded in 2002 by Stefano Buono, who was inspired to pursue medical applications for certain research conducted during his tenure at the European Organization for Nuclear Research, or CERN, with Nobel laureate Carlo Rubbia. Built first radiopharmaceutical laboratory in the Technoparc of Saint-Genis-Pouilly (France). In 2004, Achieved first Marketing Authorization to commercialize GLUSCAN® in Switzerland. In 2009, Completed the acquisition of Gipharma, an Italian pharmaceutical contract manufacturer for injectable and freeze-dried products. In 2010, Acquired BioSynthema Inc., a U.S. molecular nuclear medicine discovery company based in St. Louis, Missouri, to obtain the rights to develop and commercialize LUTATHERA® (lutetium Lu 177 dotatate). In 2018, AAA, acquired by Novartis, got FDA approval of LUTATHERA® (lutetium 177Lu oxodotreotide).

Product Portfolio: The Company's portfolio comprised of include targeted radioligand therapy in oncology and several precision imaging products mainly used in clinical oncology, cardiology, neurology and infectious/inflammatory diseases.

Key developments:

Advanced Accelerator Applications are undergoing Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents with Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma.

Why Purchase the Report?

  • Visualize the composition of the Paraganglioma Treatment Market segmentation by Treatment type, Site of origin, End-users, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Paraganglioma Treatment Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Paraganglioma Treatment Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Paraganglioma Treatment Market report would provide an access to an approx. 61 market data table, 56 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Paraganglioma Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Paraganglioma Treatment Market - Market Definition and Overview

3. Global Paraganglioma Treatment Market- Executive Summary

  • 3.1. Market Snippet by Site of origin
  • 3.2. Market snippet by Treatment Type
  • 3.3. Market Snippet by End-users
  • 3.4. Market Snippet by Region

4. Global Paraganglioma Treatment Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of paraganglioma cancers worldwide
      • 4.1.1.2. Increased Drug approvals
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of Awareness about the disease
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Paraganglioma Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Paraganglioma Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Paraganglioma Treatment Market - By Site of origin

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin Segment
  • 7.3. Market Attractiveness Index, By Site of origin Segment
      • 7.3.1.1. Carotid paraganglioma*
      • 7.3.1.2. Introduction
      • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Vagal paraganglioma
    • 7.3.3. Cervical paraganglioma
    • 7.3.4. Others

8. Global Paraganglioma Treatment Market - By Treatment type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
  • 8.3. Market Attractiveness Index, By Treatment type
    • 8.3.1. Peptide Receptor Radionuclide therapy*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Surgery
    • 8.3.3. Chemotherapy
    • 8.3.4. Radiation therapy
    • 8.3.5. Others

9. Global Paraganglioma Treatment Market - By End-users

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment
  • 9.3. Market Attractiveness Index, By End-users Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Specialty Clinics
    • 9.3.3. Cancer research institutes
    • 9.3.4. Others

10. Global Paraganglioma Treatment Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site of origin
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users

11. Global Paraganglioma Treatment Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Paraganglioma Treatment Market - Company Profiles

  • 12.1. Advanced Accelerator Applications*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Progenics Pharmaceuticals, Inc,
  • 12.3. AstraZeneca,
  • 12.4. Jubilant Life Sciences Ltd,
  • 12.5. Pfizer Inc,
  • 12.6. Teva Pharmaceutical Industries Ltd,
  • 12.7. Cipla Inc,
  • 12.8. Amneal Pharmaceuticals LLC,
  • 12.9. Apotex Inc,
  • 12.10. Ono Pharmaceuticals.

LIST NOT EXHAUSTIVE

13. Global Paraganglioma Treatment Market - Premium Insights

14. Global Paraganglioma Treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us